Crossmark

Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study

Crossref DOI link: https://doi.org/10.1186/s40360-024-00770-6

Published Online: 2024-08-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lin, Wanlong

Zeng, Yanbin

Weng, Lizhu

Yang, Jianhui

Zhuang, Wei http://orcid.org/0000-0002-1720-8882
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82304629)

Natural Science Foundation of Xiamen Municipality (3502Z202371048)
License Information

Text and Data Mining valid from 2024-08-09

Version of Record valid from 2024-08-09
More Information

Article History

Received: 17 November 2023

Accepted: 22 July 2024

First Online: 9 August 2024

Declarations

:

: Not applicable. This study was used a public, de-identified database of spontaneous reports. This study was deemed non‑human subject related research.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below